Biotech Will Recover!

G. Steven Burrill;

Publication

Article

October 15, 2002

BioPharm International

BioPharm International-10-01-2002

Volume15

Issue 10

Biotech Will Recover!

Author(s):

G. Steven Burrill

by G. Steven Burrill, Burrill & Company Beleagured by bad news since the start of the year, biotech is barely registering a pulse on Wall Street . . . but it's hardly time to write the industry's obituary.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

FDA Launches Major CGMP Review

Virus Inactivation in the 1990s ? and into the 21st Century: Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)

Process Validation: How Much to Do and When to Do It

Biotech Will Recover!

Preparing Biological Product Deviation Reports: Suggestions for Manufacturers

GMPs and Pharmaceutical Labeling

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Biotech Will Recover!

Newsletter